Ocular Therapeutix vs Xilio Therapeutics
OCUL and XLO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How OCUL and XLO compare
Ocular Therapeutix is the larger company, worth 30 times as much as Xilio Therapeutics ($1.3B against $44.5M).
Xilio Therapeutics grew revenue faster over the last twelve months (327% versus −8.1% for Ocular Therapeutix).
Xilio Therapeutics keeps more of each dollar of sales as profit, with a net margin of −34.1% compared with −579% at Ocular Therapeutix.
Xilio Therapeutics scores higher on the StockData Score (11 against 3 for Ocular Therapeutix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | OCUL | XLO |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $44.5M |
| Share price | $6.01 | $7.70 |
| Change, 1 year | −46.3% | −21.6% |
| Change, 5 years | −8.1% | −97.2% |
| Beta (5Y) | 1.53 | −0.00 |
| Employees | 325 | 76 |
| StockData Score | ||
| Total score | 3 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 3 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 25.4× | 0.7× (better) |
| P/B | 2.5× | 0.6× (better) |
| FCF yield | −19.3% (better) | −138% |
| Fair value | $5.43 | $39.24 |
| Margin of safety | −10.7% | 80.4% (better) |
| Growth | ||
| Revenue growth (TTM) | −8.1% | 327% (better) |
| Revenue growth, 5Y average | 24.4% | – |
| Profitability | ||
| Gross margin | 87.1% | – |
| Operating margin | −603% | −48.9% (better) |
| Net margin | −579% | −34.1% (better) |
| FCF margin | −490% | −95.6% (better) |
| Return on equity | −73.0% | −55.0% (better) |
| Financial health | ||
| Debt / equity | 0.14 (better) | 0.00 |
| Interest coverage | −27.5× | – |
| Current ratio | 13.11 (better) | 4.25 |
| Altman Z-score | 2.07 (better) | −3.01 |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 94.4% | 58.9% |
| Held by insiders | 2.9% | – |
| Insider net buying, 12 months | −$2.5M | $38.3K (better) |
| Short interest, % of float | 13.6% | – |
Go deeper
- OCUL stock overview
- OCUL income statement
- OCUL valuation and score
- XLO stock overview
- XLO income statement
- XLO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.